BCL6 and diffuse large B-cell lymphoma: In another study, Daigle et al. found that mutation of CREBBP in R/R DLBCL had the greatest association with tazemetostat treatment (an EZH2 inhibitor), and patients with mutations in PIM1, BCL6, HIST1H1E and TP53 lacked response to treatment [29].